Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 12.09.2024			% 5 Tage	% 1. Jan.
33.07 ^USD	+1.44%		-1.72%	+148.65%

05.09.	Transcript : Dyne Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 04:05 PM
04.09.	Dyne Therapeutics Insider kaufte Aktien im Wert von $1.057.216, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)	10.09.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	09.09.
DYN Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!	08.09.
DYN Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!	06.09.
Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing	04.09.
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm	04.09.
Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble	03.09.
Wall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing Data	03.09.
September Kicks Off With US Futures Moving Lower Ahead of Manufacturing Data	03.09.
Dyne Therapeutics Announces Key Leadership Appointments	03.09.
Dyne Therapeutics Announces Key Leadership Appointments	03.09.
Dyne Therapeutics, Inc Announces Management Changes	03.09.
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts	03.09.
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts	03.09.
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference	29.08.
Dyne Therapeutics Q2 Loss Narrows	13.08.
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights	12.08.
Dyne Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	12.08.
Facioscapulohumeral Muscular Dystrophy Pipeline 2024 \| Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc.	06.08.
Certain Common Stock of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-JUL-2024.	21.07.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Andere Sprachen

Filter